Alexion Pharmaceuticals Inc. (ALXN) said that its shareholders have approved proposed acquisition by AstraZeneca Plc. (AZN.L,AZN). The acquisition is expected to close in the third quarter of 2021.
In December 2020, AstraZeneca agreed to buy Alexion for $175 per share in cash and stock, valuing the Boston-based company at $39 billion.
As per the terms of the deal, Alexion shareholders would receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares or ADSs for each Alexion share.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.